On the other hand, as the high level of CTLA-4 expression in CLL cells is one of the good prognostic factors [19], application of CpG ODN that reduces the surface expression of CTLA-4 in leukaemic cells as a therapeutic agent seems to be an unfavourable strategy for CLL patients. Here, CTLA4 is linked to B-cell chronic lymphocytic leukemia.